Drug Discovery World

SEPTEMBER 25, 2023

Enrolment in a Phase I trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, US. An ideal universal influenza vaccine could be taken less frequently than once a year and protect against multiple strains of influenza virus.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Drug Discovery World

JANUARY 12, 2024

This week has seen a number of significant discoveries by researchers in academic institutions, in some cases in partnership with industry, emphasising the important role universities play in early-stage drug discovery. The post This week in drug discovery (8-12 January) appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs Immune Response Allergies Bacteria 52

Drug Discovery World

NOVEMBER 15, 2022

An experimental therapeutic cancer vaccine induced immune system responses that led to significant tumour regression in mice, according to investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. .

Vaccination 52

Vaccination Vaccine Allergies Immune Response 52

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Delveinsight

AUGUST 6, 2020

Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test. Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. Zydus has only said that the vaccine was well tolerated by people who received it in the first phase of the trial.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

XTalks

SEPTEMBER 8, 2020

Albany Molecular Research Inc (AMRI), a global provider of advanced drug development and manufacturing solutions, announced that they have signed a supply agreement with AstraZeneca. The company has signed on to help manufacture AstraZeneca’s COVID-19 vaccine candidate, AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus.

Manufacturing 83

Manufacturing Vaccination Vaccine Allergies 83

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. TUESDAY, Dec. © 2020 HealthDay. All rights reserved. Source link.

Vaccination 52

Vaccination Vaccine Allergies Immune Response 52

Pharmaceutical Technology

MAY 16, 2023

It will benefit from Omega’s newly opened injectable manufacturing facility, which has received clearances from Health Canada and the US Food and Drug Administration, as well as from Juno’s commercial network and product development pipeline.

Cosmetics 130

Cosmetics Allergies Manufacturing Production 130

XTalks

MAY 2, 2024

In 2023, the US Food and Drug Administration (FDA) approved a record-breaking 61 drugs, the most in history. Since January, the FDA has already signed off on more than a dozen novel drugs. The agency is reviewing applications for several highly anticipated drugs for approval in 2024.

Drugs 52

Drugs FDA Approval Sales Vaccination 52

Drug Discovery World

DECEMBER 6, 2022

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial. . The Phase I trial (IAVI G001) tested the first stage in a multi-stage HIV vaccine regimen the researchers are developing.

Vaccination 52

Vaccination Vaccine Trials Antibody 52

XTalks

NOVEMBER 16, 2020

Moderna announced today that its highly anticipated COVID-19 vaccine candidate appears to be 94.5 The news comes shortly after Pfizer and BioNTech’s mega announcement last week of their COVID-19 vaccine having shown 90 percent efficacy in an ongoing large-scale Phase III trial. The vaccine is given in two doses.

Vaccination 105

Vaccination Vaccine Trials Allergies 105

pharmaphorum

JULY 12, 2022

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA specialist Moderna. “The need for a preventive Nipah virus vaccine is significant,” he added. .

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Drug Discovery World

AUGUST 5, 2022

DDW partners with ELRIG at Drug Discovery 2022. For the first time, a series of short seminars focused on automation will be available to visitors of Drug Discovery 2022 (4-5 Oct, London, UK). For the first time, a series of short seminars focused on automation will be available to visitors of Drug Discovery 2022 (4-5 Oct, London, UK).

Drugs 52

Drugs Allergies Scientist Research 52

The Pharma Data

JANUARY 21, 2021

21, 2021 — Despite scattered media reports of severe allergic reactions to the Pfizer COVID-19 vaccine, a detailed analysis shows that such incidents are very rare, striking just 11 people for every million doses given. Tom Shimabukuro tracked data on reactions to the Pfizer vaccine soon after it was approved in December.

Vaccination 52

Vaccination Vaccine Allergies Research 52

The Pharma Data

DECEMBER 17, 2020

Advisory Committee Votes to Recommend EUA for Moderna Vaccine. 17, 2020 — The Moderna COVID-19 vaccine received recommendation from a U.S. Food and Drug Administration advisory committee on Thursday, clearing the way for it to become the second COVID-19 vaccine to be granted emergency use authorization.

Vaccination 52

Vaccination Vaccine Allergies Clinical Trials 52

Scienmag

MAY 26, 2021

Meta-analysis updates findings about common vaccines A new study looking across a large body of research finds further evidence for the safety of vaccines that are Food and Drug Administration-approved and routinely recommended for children, adults and pregnant women.

Vaccination 75

Vaccination Vaccine Drugs Research 75

The Pharma Data

JANUARY 7, 2021

Anaphylaxis Cases/Million Doses of Pfizer-BioNTech COVID-19 Vaccine Reported. per million doses administered) after receipt of the first dose of the Pfizer-BioNTech COVID-19 vaccine in the United States, according to research published in the Jan. percent) adverse events submitted to the Vaccine Adverse Event Reporting System (VAERS).

Vaccination 52

Vaccination Vaccine Allergies Research 52

The Pharma Data

MARCH 2, 2021

Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. The terms of the EUA allow use of the vaccine while more data are gathered.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. The interim analysis comprised 95 cases of symptomatic COVID-19 among volunteers.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

pharmaphorum

SEPTEMBER 29, 2022

Sanofi and Regeneron have claimed the first approval in the US for a drug for prurigo nodularis, after the FDA gave a green light to Dupixent as a treatment for adults with the rare skin disease following a priority review. Development in peanut allergy has also been discontinued, said Sanofi in its second-quarter update.

Drugs 69

Drugs Immune Response Allergies Sales 69

The Pharma Data

JANUARY 6, 2021

Rare Vaccination Side Effect in People Who Received Cosmetic Facial Fillers. Food and Drug Administration (FDA) noted that there have been a few reports of people who received cosmetic injections to smooth wrinkles or plump lips having unexpected swelling related to the COVID-19 vaccination. Here’s a look.

Vaccination 52

Vaccination Vaccine Filler Cosmetics 52

The Pharma Data

DECEMBER 14, 2020

ICU nurse Sandra Lindsay, with Long Island Jewish Medical Center in Queens, New York, received the Pfizer-BioNTech COVID-19 vaccine. Food and Drug Administration (FDA) ’ s Vaccines and Related Biological Products Advisory Committee on Thursday, December 17. billion worth of vaccines. This would be a very good thing.

Vaccination 52

Vaccination Vaccine Allergies Genome 52

Drug Discovery World

DECEMBER 13, 2023

She will be followed by Andrea Bortolato, Director of Drug Discovery at SandboxAQ, at 3pm, who will speak on ‘Combining physics-based methods with AI solutions to maximise the probability of success and speed of drug discovery and development’. Register now to show your interest.

Allergies 52

Allergies Engineer Drugs Development 52

Drug Discovery World

MARCH 23, 2023

The quality of CD8+ T cell response to two doses of the Pfizer-BioNTech Covid-19 vaccine was considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, the US study found. The Pfizer-BioNTech vaccine uses parts of the SARS-CoV-2 spike protein to elicit an immune response without causing infection.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52

Drug Discovery World

JANUARY 21, 2024

Technology is increasingly important to drug discovery. Advances in this area are having a positive effect on both the commercial success of drug discovery and development organisations, as well as benefitting the health and wellbeing of the global population.

Protein 52

Protein Vaccination Vaccine Development 52

Drug Discovery World

JANUARY 22, 2024

Sponsored by Integra Biosciences and Hamamatsu Corporation, it will explore technologies being used for drug discovery and how they get from lab to patient. Simon Bushell, SVP of Molecular Discovery at Entact Bio, will present: ‘Proximity-inducing drugs: Using technological innovation to build the next generation of medicine’.

Engineer 59

Engineer Immune Response Drugs Vaccination 59

The Pharma Data

JANUARY 25, 2021

Severe Allergic Reactions to Moderna COVID-19 Vaccine Rare: CDC. Only 10 people in the entire United States have had severe allergic reactions to Moderna’s COVID-19 vaccine, out of more than 4 million who’ve received the first dose, a new government report shows. minutes after vaccination. In December, U.S.

Allergies 52

Allergies Vaccination Vaccine Containment 52

The Pharma Data

DECEMBER 17, 2020

Food and Drug Administration (FDA) ’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended the agency grant Moderna ’s COVID-19 vaccine emergency use authorization (EUA). A week ago, the FDA granted Pfizer-BioNTech’s COVID-19 vaccine EUA on Friday the day after the same adcom voted 16-1-1.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. Targeted drug combo attacks breast cancer brain metastases in mice.

Vaccination 53

Vaccination Vaccine Research Trials 53

NY Times

MARCH 23, 2021

According to federal officials, an independent panel of medical experts said the promising results announced by the company on Monday may have relied on “outdated information.”.

Vaccination 140

Vaccination Vaccine Trials Clinical Trials 140

pharmaphorum

APRIL 28, 2021

Sanofi’s much anticipated drug for both haemophilia A and B – fitusiran – could be filed in 2022 despite a problem with blood clots in some patients in late-stage testing. . The RNA interference (RNAi) drug is designed to treat haemophilia A and B patients by suppressing antithrombin (AT), a protein that inhibits blood clotting.

Drugs 52

Drugs Sales Allergies RNA 52

pharmaphorum

JUNE 24, 2022

pharmaphorum editor in chief Jonah Comstock talks to Philip Gomez, CEO of Siga Technologies, about how his company’s antiviral drug can play a crucial role in addressing monkeypox cases. One of the new countries stockpiling the drug is in Europe. I was part of the team that worked on the first SARS vaccine that went into humans.

Vaccination 52

Vaccination Vaccine Drugs Allergies 52

XTalks

NOVEMBER 30, 2023

In 2022, the US Food and Drug Administration (FDA) granted approval to the medication Sunlenca (lenacapavir) for adults living with multi-drug resistant HIV-1 infection. Developed by Gilead, Sunlenca is the first drug in a novel class known as capsid inhibitors to receive FDA approval for treating HIV-1.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

pharmaphorum

JULY 28, 2022

Sanofi recently raised its full-year sales prediction for the product from €10 billion to €13 billion, thanks in part to uptake of the drug in eosinophilic oesophagitis, a new indication that was approved by the FDA in May. Development in peanut allergy has also been discontinued, said Sanofi in its second-quarter update.

Sales 59

Sales Allergies Vaccination Vaccine 59

The Pharma Data

DECEMBER 2, 2020

2, 2020 – Britain became the first Western country to allow emergency use of a coronavirus vaccine on Wednesday, after approving Pfizer’s candidate in the race to inoculate millions of people around the globe. But there are daunting obstacles to the vaccine’s delivery to the masses. WEDNESDAY, Dec.

Vaccination 40

Vaccination Vaccine Nurses Containment 40

Drug Discovery World

JANUARY 31, 2024

SLAS 2024 Supplement, Volume 25 – Issue 1, Winter 2023/2024 The post The journey from lab to patient appeared first on Drug Discovery World (DDW). The more time scientists have for science, the better.

Gene Therapy 52

Gene Therapy Allergies Scientist Gene 52

NY Times

NOVEMBER 30, 2020

The first shots could be given as early as Dec. 21, if authorization is granted.

Vaccination 145

Vaccination Vaccine RNA Allergies 145